Clinical significance of serum NM23‐H1 protein in neuroblastoma

We have previously reported that NM23 genes are overexpressed in various hematological malignancies and that serum NM23‐H1 protein levels are useful for predicting patient outcomes. In this study we assessed the clinical implications of serum NM23‐H1 protein on neuroblastoma. We examined serum NM23‐H1 protein levels in 217 patients with neuroblastoma, including 131 found by mass‐screening and 86 found clinically by an enzyme‐linked immunosorbent assay, and determined the association between levels of this protein, and known prognostic factors or the clinical outcome. The serum NM23‐H1 protein level was higher in neuroblastoma patients than in control children (P